Forecasts by Vaccine Type (Conjugate, Polysaccharide, Others), by Vaccine Brand (Bexsero, Menactra, Menveo, Others), by End-users (Pediatric, Adult, Travelers) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Impact and Recovery Pattern Analysis.

New York, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Meningococcal Vaccines Market Report 2023-2033" - https://www.reportlinker.com/p06417096/?utm_source=GNW


The Meningococcal Vaccines Market Report 2023-2033: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.


Increasing Prevalence of Meningitis Driving Market Growth

Increasing adoption of meningococcal vaccines and the growing prevalence of meningitis and other viral diseases in developed as well as developing regions is anticipated to drive market growth. Also, the growing investment in RandD and novel drug launches for the treatment of viral diseases is further boosting the market growth. The developed regions including the U.S., Japan, and Europe accounted for a large share in the market is due to the well-developed healthcare infrastructure and better healthcare awareness in developed countries compared to developing countries. Thus, the demand for advanced and more efficient drugs is high in these regions. Whereas the market in emerging economies such as China, India, and South Africa is growing at a high pace owing to government initiatives, growing respiratory health awareness, and increasing disposable income.


What Questions Should You Ask before Buying a Market Research Report?

• How is the meningococcal vaccines market evolving?

• What is driving and restraining the meningococcal vaccines market?

• How will each meningococcal vaccines submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2033?

• How will the market shares for each meningococcal vaccines submarket develop from 2023 to 2033?

• What will be the main driver for the overall market from 2023 to 2033?

• Will leading meningococcal vaccines markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?

• How will the market shares of the national markets change by 2033 and which geographical region will lead the market in 2033?

• Who are the leading players and what are their prospects over the forecast period?

• What are the meningococcal vaccines projects for these leading companies?

• How will the industry evolve during the period between 2023 and 2033? What are the implications of

meningococcal vaccines projects taking place now and over the next 10 years?

• Is there a greater need for product commercialisation to further scale the meningococcal vaccines market?

• Where is the meningococcal vaccines market heading and how can you ensure you are at the forefront of the market?

• What are the best investment options for new product and service lines?

• What are the key prospects for moving companies into a new growth path and C-suite?


You need to discover how this will impact the meningococcal vaccines market today, and over the next 10 years:

• Our 214-page report provides 83 tables and 132 charts/graphs exclusively to you.

• The report highlights key lucrative areas in the industry so you can target them – NOW.

• It contains in-depth analysis of global, regional and national sales and growth.

• It highlights for you the key successful trends, changes and revenue projections made by your competitors.


This report tells you TODAY how the meningococcal vaccines market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.


Forecasts to 2033 and other analyses reveal commercial prospects

• In addition to revenue forecasting to 2033, our new study provides you with recent results, growth rates, and market shares.

• You will find original analyses, with business outlooks and developments.

• Discover qualitative analyses (including market dynamics, drivers, opportunities, and restraints), Porter’s Five Forces Analysis, PEST Analysis and recent developments.


This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.


Segments Covered in the Report


Vaccine Type

• Conjugate

• Polysaccharide

• Others


Vaccine Brand

• Bexsero

• Menactra

• Menveo

• Others


End-users

• Pediatric

• Adult

• Travelers


In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 21 leading national markets:


North America

• U.S.

• Canada


Europe

• Germany

• UK

• France

• Italy

• Spain

• Russia

• Rest of Europe


Asia Pacific

• Japan

• China

• India

• Australia

• South Korea

• Rest of Asia Pacific


Latin America

• Brazil

• Mexico

• Rest of Latin America


MEA

• GCC

• South Africa

• Rest of MEA


The report also includes profiles and for some of the leading companies in the Meningococcal Vaccines Market, 2023 to 2033, with a focus on this segment of these companies’ operations.


Leading companies and the potential for market growth

• BIO-MED

• GSK plc

• Incepta Pharmaceuticals Ltd.

• Merck and Co., Inc.

• Pfizer Inc.

• Sanofi

• Serum Institute of India Pvt. Ltd.

• Walvax Biotechnology Co., Ltd.

• Zhi Fei Biological


Overall world revenue for Meningococcal Vaccines Market, 2023 to 2033 in terms of value the market will surpass US$3,443.4 million in 2023, our work calculates. We predict strong revenue growth through to 2033. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.


How will the Meningococcal Vaccines Market, 2023 to 2033 report help you?

In summary, our 210+ page report provides you with the following knowledge:


• Revenue forecasts to 2033 for Meningococcal Vaccines Market, 2023 to 2033 Market, with forecasts for Vaccine Type, Vaccine Brand, and End-users, each forecast at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.


• Revenue forecasts to 2033 for five regional and 21 key national markets – See forecasts for the Meningococcal Vaccines Market, 2023 to 2033 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.


• Prospects for established firms and those seeking to enter the market – including company profiles for 9 of the major companies involved in the Meningococcal Vaccines Market, 2023 to 2033.


Read the full report: https://www.reportlinker.com/p06417096/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001